Q32 Bio Reports Topline Results for SIGNAL-AA Part B
Q32 Bio Inc. released 36-week topline results for the Part B of its Phase 2a SIGNAL-AA clinical trial. These data are critical for assessing the efficacy and safety profile of bempikibart in treating alopecia areata.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day